Keudell/Morrison Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Keudell/Morrison Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,105	Closed	-$9K	–	152
2020 Q2	$9K	Hold	10,105	–	–	0.01%	141
2020 Q1	$8K	Sell	10,105 -1,600	-14%	-$1.59K	0.01%	136
2019 Q4	$10K	Hold	11,705	–	–	0.01%	154
2019 Q3	$11K	Sell	11,705 -7,370	-39%	-$7.63K	0.01%	151
2019 Q2	$19K	Hold	19,075	–	–	0.02%	142
2019 Q1	$25K	Buy	+19,075	New	+$23.7K	0.02%	138

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Keudell/Morrison Wealth Management's LCTX Position: Q3 2020 in Review

Keudell/Morrison Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 10,105 shares — an estimated $9K sold.

Keudell/Morrison Wealth Management first reported a position in LCTX in Q1 2019 and held it in 6 quarters. The position peaked at $25K in Q1 2019. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

Keudell/Morrison Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
Keudell/Morrison Wealth Management sold 10,105 Lineage Cell Therapeutics shares in Q3 2020, an estimated $9K.
Keudell/Morrison Wealth Management first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 6 quarters.
Keudell/Morrison Wealth Management's Lineage Cell Therapeutics position peaked at $25K in Q1 2019.
75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Keudell/Morrison Wealth Management's 13F filing for Q3 2020, filed 20 Oct 2020.